March 13, 2018 / 7:33 AM / 2 months ago

BRIEF-Sosei Group regains worldwide rights from Teva to develop and commercialize novel small molecule CGRP antagonists for migraine and other severe headaches

March 13 (Reuters) - Sosei Group Corp

* Says co has regained worldwide rights from Teva Pharmaceutical Industries Ltd., to develop and commercialize lead candidate HTL0022562 and other novel small molecule CGRP antagonists for the treatment of migraine and other severe headaches

Source text in Japanese: goo.gl/rXbEp7

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below